Gilead Sciences Aktie News

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due in part to concerns about how Robert F. Kennedy's nomination for Health and Human Services Secretary might impact the industry.

AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.

Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.

LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, and MEDSIR (www.medsir.org), a Spanish and US-based, international and innovative research organization in clinical oncology, today announced that the first pa...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company's Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir—the company's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-expos...